Biotechnology · Los Angeles, California, United States
$13.61
-0.37% (-$0.05)2026-08-24
Net Income-$11.6M
EPS$-0.36
Market Cap$973.6M
Price Performance
Historical data including institutional events
Company Profile
I
Ilya Rachman
CEO & Executive Director
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
The companyâ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
